



Best Available Copy

Dkt. 75990-B/JPW/BJA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul Simmons et al.
Serial No.: 10/813,747
Filed : March 29, 2004
For : MESENCHYMAL PRECURSOR CELL

1185 Avenue of the Americas
New York, New York 10036

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

REVOCATION OF POWER OF ATTORNEY AND APPOINTMENT OF NEW ATTORNEYS

Angioblast Systems, Incorporated ("Angioblast"), 279 East 44th Street, New York, NY 10017, is the assignee of the right and interest to the above-identified application by virtue of an assignment from Medvet Sciences Pty Ltd, a copy of which is attached hereto as Exhibit A and is being submitted to the United States Patent and Trademark Office for recording. Angioblast hereby revokes all powers of attorney previously granted and appoints the following attorneys: John P. White (Reg. No. 26,678); Christopher C. Dunham (Reg. No. 22,031); Norman H. Zivin (Reg. No. 25,385); William E. Pelton (Reg. No. 25,702); Robert D. Katz (Reg. No. 30,141); Peter J. Philips (Reg. No. 29,691); Paul Teng (Reg. No. 40,837); Alan J. Morrison (Reg. No. 37,399); and Gary J. Gershik (Reg. No. 39,992) and each of them, all c/o

Applicants: Paul Simmons et al.
Serial No.: 10/813,747
Filed : March 29, 2004
Page 2

York 10036 (Tel. (212) 278-0400), its attorneys, each with full power of substitution and revocation, to prosecute this application, to make alterations and amendments therein, to receive the patent, and to transact all business in the U.S. Patent and Trademark Office in connection therewith.

Please address all communications and direct all telephone calls regarding this application to:

JOHN P. WHITE
COOPER & DUNHAM LLP (Customer No. 23432)
1185 AVENUE OF THE AMERICAS
NEW YORK, NEW YORK 10036
TEL. (212) 278-0421

Applicants: Paul Simmons et al.
Serial No.: 10/813,747
Filed : March 29, 2004
Page 3

I certify that I am authorized to sign this Revocation of Power
of Attorney and Appointment of New Attorneys on behalf of
Angioblast Systems, Incorporated.

Angioblast Systems, Incorporated

By: _____

Name: Silviu Itescu
Title: Director

Date: _____

4/28/06

Intellectual Property Assignment Deed

Medvet Sciences Pty Ltd
ABN 15 008 089 745

and

Angioblast Systems, Incorporated

Table of Contents (ctd)

2

Schedule 2

21

Intellectual Property Assignment Deed

Date 7th October 2004

Parties

1. Medvet Sciences Pty Ltd ABN 15 008 089 745 of 38 Payneham Road, Stepney, South Australia, 5069 Australia (Medvet)
2. Angloblast Systems, Incorporated of 279 East, 44th Street, New York, NY 10017 United States of America (Angloblast)

Background

Table of Contents (ctd)

4

Operative Provisions

1. Definitions and interpretation

Table of Contents (ctd)

5

Table of Contents (ctd)**6**

Intellectual Property Rights means all present and future intellectual and industrial property rights conferred by statute, at common law or in equity and wherever existing, including:

- (d) patents, designs, copyright, rights in circuit layouts, plant breeder's rights, trade marks, know how, brand names, domain names, inventions, product names, trade secrets and any other rights subsisting in the results of intellectual effort any field, whether or not registered or capable of registration;
- (e) any application or right to apply for registration of any of those rights;
- (f) any registration of any of those rights or any registration of any application referred to in paragraph (b); and
- (g) all renewals and extensions of these rights;

Patent Family 1 means all rights and interests in and to issued patents and pending patent applications in any country, including all substitutions, continuations, continuations-in-part, divisional, supplementary protection certificates, renewals, all letters patent granted thereon, and all reissues, re-examinations, extensions, confirmations, revalidations, registrations and patents of addition thereof that result either directly or indirectly from the following patent applications which are sought and obtained:

- (a) 'Mesenchymal Precursor Cell' PCT/AU00/00822;
- (b) 'Mesenchymal Precursor Cell' Australian Patent Application No. 56636/00;
- (c) 'Mesenchymal Precursor Cell' U.S. Patent Application No. 10/030411;
- (d) Continuation-in-Part U.S. Patent Application No.10/813,747;
- (e) 'Perivascular Mesenchymal Precursor Cells' PCT/AU2004/00416; and

Table of Contents (ctd)

7

- (f) U.S. Continuation-in-Part application related to USSN10/030411 titled 'Mesenchymal Precursor Cell and use thereof in the repair of bone defects and fractures in mammals';

Patent Family 2 means 'Perivascular Mesenchymal Precursor Cell Induced Blood Vessel Formation' PCT/AU2004/00417 patent and all rights and interests in and to issued patents and pending patent applications in any country, including all substitutions, continuations, continuations-in-part, divisional, supplementary protection certificates, renewals, all letters patent granted thereon, and all reissues, re-examinations, extensions, confirmations, revalidations, registrations and patents of addition resulting either directly or indirectly from this patent;

Technology means:

- (i) Patent Family 1;
(j) Patent Family 2;

Table of Contents (ctd)

8

Table of Contents (ctd)**9****2. Assignment****2.1 Technology Assignment**

Medvet hereby assigns to Angioblast absolutely and beneficially, such assignment to be effective from the date of execution of this Deed, the whole of its rights, title and interest, whether presently existing or which arises at a date after the date of this Deed in and to any Intellectual Property Rights subsisting in the Technology including:

- (i) the right to apply for and register in any country worldwide such Intellectual Property Rights; and
- (ii) the right to claim (and retain) any damages and other remedies (including but not limited to an account of profits) for past infringement of and wrongful interference of such Intellectual Property Rights by third parties (whether or not they arose prior to the date this Deed came into effect).

(Assigned Technology).

Table of Contents (ctd)

10

Table of Contents (ctd)

11

Table of Contents (ctd)

12

Table of Contents (ctd)

13

Table of Contents (ctd)

14

Table of Contents (ctd)

15

Table of Contents (ctd)

16

Table of Contents (ctd)

17

Table of Contents (ctd)

18

Table of Contents (ctd)

19

Schedule 1

Table of Contents (ctd)

20

Table of Contents (ctd)

21

Schedule 2

Table of Contents (ctd)

Table of Contents (ctd)

23

Executed as a deed.

Executed by Medvet Sciences Pty Ltd ABN
15 008 849 745 in accordance with section
127(1) of the Corporations Act 2001 (Cth):





Signature of director




Name (please print)


Executed by Angloblast Systems,
Incorporated in accordance with its
Constitution by its duly authorised officers


Signature of authorised officer
Name (please print)


Signature of director or company secretary
*delete whichever does not apply


Name (please print)


Signature of authorised officer


Name (please print)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.